As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

The new data from the Phase 3 C-POST trial presented at ASCO 2025 demonstrated that cemiplimab (Libtayo) reduced the risk of ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...